Noven Announces 2007 Earnings Release Date

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced its 2007 earnings release date.

On March 13th, before the U.S. market opens, Noven is scheduled to issue a press release announcing its financial results for the quarter and year ended December 31, 2007. At 8:30 a.m. Eastern Time the same day, a conference call with management will be broadcast live via the Internet at www.noven.com, and thereafter a rebroadcast will be accessible at the same site for at least two weeks. A taped replay of the call will be available beginning March 13th through March 15th by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering account number 286 and conference ID number 275402.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s leading transdermal products utilize its proprietary DOT Matrix® drug delivery technology and include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD. Oral products currently offered through Noven’s psychiatry/CNS marketing and sales organization consist of Pexeva® (paroxetine mesylate) and Lithobid® (lithium carbonate). Developmental products include Stavzor™ (delayed release valproic acid capsule) and Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product for vasomotor symptoms. See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916